Evaluation of Serum Auto Antibodies in Multiple Sclerosis Patients: A Case Control Study
International Clinical Neuroscience Journal,
Vol. 4 No. 1 (2017),
15 Farvardin 2017
,
Page 25-28
https://doi.org/10.22037/icnj.v4i1.12550
Abstract
Background and Purpose: Multiple sclerosis (MS) is believed to be an immune-mediated disorder that develops from an interaction of the individual's genetic and as yet unidentified environmental causes. The prevalence of auto-antibodies in multiple sclerosis patients and their clinical associations vary in various studies. The aim of this study was to determine serum auto antibodies in multiple sclerosis patients.
Methods: This cross-sectional case-control study investigated anti-phospholipids antibody (APLA), antinuclear antibody (ANA), anti-cardiolipin antibody (ACLA), anti-neutrophilic antibodies (ANCA), anti-beta-2-glycoprotein I (anti β2GPI), and anti-double strand DNA (anti-ds-DNA) in 54 consecutive patients with relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) who were referred to Imam Reza outpatient clinic of Shiraz University of Medical Sciences. The results were compared with 25 healthy individuals as the control group.
Results: Among 54 patients with relapsing-remitting MS or clinically isolated syndrome, at least one abnormal tests were found in 15 patients (27.9%), 6 (11.1%) had positive antinuclear antibodies, 3 (5.6%) had positive anti cardiolpin antibody (ACLA) and P-ANCA was positive in 2(3.7%) of patients and C-ANCA was positive in 1(1.9%) of patients. None of the patients had any clinical manifestations other than MS symptoms. In the patient group, anti-ds-DNA antibody was positive in 5.6% of cases; statistically it had no significant difference with the control group (0%) (P=0.7), but anti- phospholipids antibody (APLA) and B2GPI were negative in all patient and control groups. The females had more positive auto-antibodies in comparison to males, but statistically their difference was not significant.
Conclusion: The results of this study showed that a significant number of patients with relapsing remitting multiple sclerosis and clinically isolated syndrome have positive serum auto-antibodies tests (including ANA, ANCA and ACLA) without clinical expression of any other autoimmune disease.
- multiple sclerosis
- auto-antibodies
- prevalence
- clinically isolated syndrome
How to Cite
References
Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014;122:231-66.
Marrie RA. "Environmental risk factors in multiple sclerosis aetiology". Lancet Neurol. 2004;3 (12): 709–18.
Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol. 2004;61(10):1613-5.
Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372:1502-17.
Tsang BK, Macdonell R. "Multiple sclerosis- diagnosis, management and prognosis". Australian family physician. 2011;40 (12):948–55.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 201415;83(3):278-86.
Roach ES. Is multiple sclerosis an autoimmune disorder? Arch Neurol. 2004; 61:1615-16.
Ramagopalan SV, Dyment DA, Valdar W, Herrera BM, Criscuoli M, Yee IM, et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol. 2007;6(7):604-10.
Szmyrka-Kaczmarek M, Pokryszko-Dragan A, Pawlik B, Gruszka E, Korman L, Podemski R, et al. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus. 2012; 21(4):412-20.
Bonaci-Nikolic B, Jeremic I, Andrejevic S, Sefik-Bukilica M, Stojsavljevic N, Drulovic J. Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis. Lupus. 2009; 18(1):78-80.
Bitsch A, Dressel A, Meier K, Bogumil T, Deisenhammer F, Tumani H, et al. Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. J Neurol. 2004; 251(12):1498-501.
Koudriavtseva T, D'Agosto G, Mandoj C, Sperduti I, Cordiali-Fei P. High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory–thrombotic processes. Neurological. 2014;35(11):1737-41.
Garg N, Zivadinov R, Ramanathan M, Vasiliu I, Locke J, Watts K, et al. Clinical and MRI correlates of auto reactive antibodies in multiple sclerosis patients. J Neuroimmunol. 2007; 187(1-2):159-65.
Wei Qiu, Bundell C, Wu JS, Castley A, James I, Hollingsworth P, et al. Low level of systemic autoimmunity in Western Australian multiple sclerosis patients. Mult Scler. 2010;16(3):351-4.
Szmyrka-Kaczmarek M, Pokryszko-Dragan A, Pawlik B, Gruszka E, Korman L, Podemski R, et al. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus. 2012; 21(4):412-20.
Collard RC, Koehler RP, Mattson DH. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology. 1997; 49: 857–861.
Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol. 1998;44(4):629-34.
Miyagishi R, Fukazawa T, Hamada T, Moriwaka F, TashiroK. Two cases of recurrent optic neuritis (OPN) and acute transverse myelopathy (ATM) with associated anticardiolipin antibodies. RinshoShinkeigaku. 1992; 32(10):1121-4.
- Abstract Viewed: 710 times
- PDF Downloaded: 1416 times